Cardiovascular Drug Update: NewAmsterdam Pharma and Menarini say the EMA’s CHMP has issued a positive opinion for marketing authorization in Europe of Ubeslo® (obicetrapib) and Evlarco® (obicetrapib plus ezetimibe), based on Phase 3 results, with an EU decision expected in 2H26. Disability Benefits Reminder: The UK DWP warns PIP claimants that taking a holiday longer than four weeks can trigger penalties, including payment suspension, unless they notify the department and report other major changes. Citizenship Test Details: The UK outlines the “Life in the UK Test” for foreign applicants, including booking rules, cost, and the 45-minute, 24-question format. Medtech Financing in the Region: Healthcare Holding Schweiz AG has closed CHF 80 million in syndicated financing to fund further medtech acquisitions and growth, with Liechtensteinische Landesbank among the lenders. Health & Mobility Policy Context: A broader debate on public service media funding and public trust is resurfacing, with implications for how health and welfare information reaches communities. Travel & Health Planning: Separate travel updates include visa rules and passport ranking shifts, which can affect how people plan time away and access services. Digital Economy Note: A report on Estonia’s unicorn-per-capita ranking highlights how digital ID and startup ecosystems can attract investment—while also warning that such metrics can mislead policymakers.